Aptus Pharma Board Approves Authorized Capital Increase and 3:2 Bonus Issue

Aptus Pharma Limited's board of directors approved significant corporate restructuring proposals during its meeting held on March 24, 2026. The pharmaceutical company's board sanctioned an authorized share capital enhancement and recommended a 3:2 bonus equity shares issue, with comprehensive regulatory compliance measures in place.

Authorized Share Capital Enhancement

The board approved a substantial increase in the company's authorized share capital structure, subject to shareholder approval. The enhancement represents a strategic expansion to support future growth initiatives and corporate flexibility.

Parameter: Current Structure Proposed Structure Authorized Capital: ₹7,15,00,000 ₹25,00,00,000 Number of Shares: 71,50,000 shares 2,50,00,000 shares Face Value: ₹10 per share ₹10 per share

Bonus Equity Shares Recommendation

The board recommended issuing bonus equity shares to existing shareholders in a 3:2 ratio. The bonus shares will be issued by capitalizing ₹10,29,00,000 from the securities premium account, with adequate reserves available for the proposed capitalization.

Bonus Issue Details: Specifications Bonus Ratio: 3:2 Entitlement: 3 bonus shares for every 2 existing shares Total Bonus Shares: 1,02,90,000 equity shares Face Value: ₹10 per share Capitalization Amount: ₹10,29,00,000 Source of Funds: Securities Premium Account

Share Capital Structure Impact

The bonus issue will significantly transform the company's paid-up share capital structure, with the total number of shares increasing substantially post-implementation.

Share Capital Impact: Pre-Bonus Issue Post-Bonus Issue Number of Shares: 68,60,000 1,71,50,000 Paid-up Capital: ₹6,86,00,000 ₹17,15,00,000 Face Value: ₹10 per share ₹10 per share

Postal Ballot and E-Voting Process

The board approved the postal ballot notice along with explanatory statements for both resolutions. Central Depository Services Limited (CDSL) has been appointed as the e-voting agency, with a scrutinizer designated for conducting the process transparently. The record date for determining bonus share entitlement will be announced in due course.

Regulatory Compliance and Timeline

The company has obtained statutory auditor certification confirming adequate securities premium reserves of ₹10,67,63,656 as of March 24, 2026. The proposed bonus shares are expected to be credited within two months from board approval, on or before May 23, 2026. Managing Director Tejash Hathi (DIN: 03151221) signed the regulatory communication, with the board meeting conducted from 5:00 PM to 7:15 PM on March 24, 2026.

Aptus Pharma Limited has officially scheduled a board meeting for March 24, 2026, to deliberate on significant corporate actions including the issuance of bonus equity shares and an increase in authorized share capital.

Board Meeting Details

The company has issued a formal notice to BSE Limited under Regulation 29 of SEBI Listing Regulations, confirming that the board meeting will be held at their registered office in Rajkot, Gujarat. The meeting agenda includes two key proposals that require board consideration and subsequent shareholder approval.

Meeting Details: Information Date: March 24, 2026 Venue: Rajkot, Gujarat Security Code: 544529 Script Symbol: APPL

Key Agenda Items

The board will consider two significant corporate actions during the meeting. First, the proposal to increase the company's authorized share capital, which will require member approval if recommended by the board. Second, the consideration and recommendation of bonus equity shares, also subject to shareholder approval.

Proposals: Status Authorized Share Capital Increase: Subject to member approval Bonus Equity Shares: Subject to member approval

Trading Window Closure

In compliance with SEBI insider trading regulations, the company has announced a trading window closure for all designated persons and their immediate relatives. The trading restriction will be effective from March 18, 2026, through March 26, 2026, covering the period around the board meeting deliberations.

Corporate Action Significance

Bonus shares represent additional equity shares distributed to existing shareholders without requiring additional payment, typically undertaken to reward shareholders and improve market liquidity. The proposed increase in authorized share capital would provide the company with greater flexibility for future capital-raising activities and corporate restructuring initiatives.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.